Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by ScienceFirston Apr 25, 2023 8:46am
59 Views
Post# 35412002

RE:New Press Release - Ventripoint Announces Sponsorship of the 56th Annual Meeting of the Association for European Paediatric and Congenital Cardiology

RE:New Press Release - Ventripoint Announces Sponsorship of the 56th Annual Meeting of the Association for European Paediatric and Congenital CardiologyMore perspectives from Dr. Adams

Attached is a news release which has been released.  Here are some background points:
 
1. The AEPC is a major event in our 2023 schedule of conferences and the presentation by Dr. Laser is the first podium presentation we have had in some years.
2. Dr. Laser has been a strong champion for the VMS products and has published a number of excellent research studies such as: "Real-time 3D-echocardiography of the right ventricle-paediatric reference values for right ventricular volumes using knowledge-based reconstruction: a multicentre study" Quant Imaging Med Surg. 2021;11(7):2905-2917. wherein 74.5% of cases could be analyzed.  This was a major achievement and showed real-time 3D-echocardiography (also known as 4D) with VMS+ analysis could be used as a clinical tool.
3. The booth is always filled with people after such a presentation and so we will have a full team there to collect contact information and follow up after the event.
4. Germany, where Dr. Laser is a key opinion leader, is an excellent market for us and AngioPro our European distributor, who is based in Germany, has now hired an application specialist to do on-site demonstrations, which are critical to the decision to adopt the VMS+ products.
 
Thank you for your continued interest and support as we go forward to improve cardiac diagnostics for everyone everywhere and especially for children.
 
Regards,
 
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT
www.ventripoint.com
519-803-6937

<< Previous
Bullboard Posts
Next >>